Keyphrases
Clinical Characteristics
100%
Albumin-to-creatinine Ratio
100%
Albuminuria
100%
Risk Markers
100%
Clinical Change
100%
Non-responders
33%
Baseline Characteristics
22%
Change from Baseline
22%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
11%
Randomized Controlled Clinical Trial
11%
Type 2 Diabetic Patients
11%
Non-response
11%
Cardiovascular Risk Markers
11%
Estimated Glomerular Filtration Rate
11%
Metabolic Variables
11%
Large Reduction
11%
Pooled Analysis
11%
Adjusted Means
11%
Systolic Blood Pressure
11%
Hemoglobin A1c (HbA1c)
11%
Clinical Features
11%
Medicine and Dentistry
Albuminuria
100%
Dapagliflozin
100%
Creatinine
100%
Urinary System
100%
Hemoglobin A1c
11%
Systolic Blood Pressure
11%
Cardiovascular System
11%
Controlled Clinical Trial
11%
Pooled Analysis
11%
Glomerular Filtration Rate
11%
Patient with Type 2 Diabetes
11%
Cardiovascular Risk
11%
Sodium Glucose Cotransporter 2 Inhibitor
11%
Clinical Feature
11%
Body Weight
11%
Pharmacology, Toxicology and Pharmaceutical Science
Dapagliflozin
100%
Albuminuria
100%
Creatinine
100%
Hemoglobin A1c
11%
Controlled Clinical Trial
11%
Cardiovascular Risk
11%
Non Insulin Dependent Diabetes Mellitus
11%
Sodium Glucose Cotransporter 2 Inhibitor
11%
Clinical Feature
11%
Immunology and Microbiology
Albumin
100%
Cotransporter
11%
Glomerulus Filtration
11%
Systolic Blood Pressure
11%
Body Weight
11%